Pharmacokinetics describes what happens to a substance's concentration over time. It is an important part of drug development, but similar exposure between groups is not the same as proof that every clinical risk is the same.
A 2026 cagrilintide publication reported two single-dose studies: 33 participants in the renal-function study and 32 in the hepatic-function study. Each compared people with normal function and different degrees of impairment. The investigators found no clinically relevant pharmacokinetic differences within the limitations of those small studies.
The design is the key boundary. Participants were observed after a single study exposure, not through years of ordinary treatment. Small subgroups cannot reliably exclude uncommon adverse events, and a finding about exposure does not answer every question about illness severity, concurrent medicines or repeated administration.
The title can therefore be read too broadly. “Does not affect” refers to the investigation performed, not an unlimited guarantee for all people with kidney or liver disease. The authors themselves acknowledge the sample-size limitation. A reader should preserve that qualification rather than detach the reassuring phrase from the methods.
Absence of a serious event in a small sample is also different from evidence that such an event is impossible. The opportunity to observe an uncommon event depends on how many people were followed, for how long and under what conditions. Those considerations remain relevant even when the measured concentration curves look similar.
For an individual, kidney or liver disease is part of a clinical assessment, not an invitation to derive a regimen from a journal conclusion. A licensed clinician would need to evaluate the person's diagnosis, current condition and other treatments. This article provides no exposure adjustment advice and no permission for investigational use.
The useful takeaway is narrow but valuable: these studies contribute organ-function pharmacokinetic evidence to development. They do not establish broad chronic safety, prove suitability of another product or replace an approved prescribing framework. Keeping a single-dose result within its actual scope makes it more informative, not less.